On the structure and function of apolipoproteins: More than a family of lipid-binding proteins

Progress in Biophysics and Molecular Biology

Volumn 83, Issue 1, 2003, Pages 47-68

  Bolanos Garcia, Victor Martin ^a   Miguel, Ricardo Nunez ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amphipathic helices; Amyloid formation; Apolipoprotein structure; Kinetic stability; Lipid binding proteins

Indexed keywords

EID: 0038737056     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0079-6107(03)00028-2     Document Type: Review

References (115)

1. Aalto-Setala K., Weinstock P.H., Bisgaier C.L., Wu L., Smith J.D., Breslow J.L. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37:1996;1802-1811.
2. Allan C.M., Taylor J.M. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. J. Lipid Res. 37:1996;1510-1518.
3. Allan C.M., Walker D., Segrest J.P., Taylor J.M. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics. 28:1995;291-300.
4. Andreola A., Bellotti V., Giorgetti S., Mangione P., Obici L., Stoppini M., Torres J., Monzani E., Merlini G., Sunde M. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. J. Biol. Chem. 278:2003;2444-2451.
5. Arakawa R., Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J. Biol. Chem. 277:2002;22426-22429.
6. Baker D., Agard D.A. Kinetics versus thermodynamics in protein folding. Biochemistry. 33:1994;7505-7509.
7. Bengtsson G., Olivecrona T. Activation of lipoprotein lipase by apolipoprotein CII. Demonstration of an effect of the activator on the binding of the enzyme to milk-fat globules. FEBS Lett. 147:1982;183-187.
8. Bergstrom J., Murphy C., Eulitz M., Weiss D.T., Westermark G.T., Solomon A., Westermark P. Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem. Biophys. Res. Commun. 285:2001;903-908.
9. Bielicki J.K., Oda M.N. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 41:2002;2089-2096.
10. Bolanos-Garcia V., Soriano-Garcia M., Mas-Oliva J. CETP and exchangeable apoproteins. common features in lipid binding activity Mol. Cellular Biochem. 175:1997;1-10.
11. Bolanos-Garcia V.M., Mas-Oliva J., Ramos S., Castillo R. Phase transitions in monolayers of human Apolipoprotein C-I. J. Phys. Chem. B. 103:1999;6236-6242.
12. Bolanos-Garcia V.M., Ramos S., Castillo R., Xicohtencatl-Cortes J., Mas-Oliva J. Monolayers of apolipoproteins at the air/water interface. J. Phys. Chem. B. 105:2001;5757-5765.
13. Borhani D.W., Rogers D.P., Engler J.A., Brouillette C.G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA. 94:1997;12291-12296.
14. Borhani D.W., Engler J.A., Brouillette C.G. Crystallization of truncated human apolipoprotein A-I in a novel conformation. Acta Crystallogr. D. 55:1999;1578-1583.
15. Bowie J.U., Luthy R., Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 253:1991;164-170.
16. Breiter D.R., Kanost M.R., Benning M.M., Wesenberg G., Law J.H., Wells M.A., Rayment I., Holden H.M. Molecular structure of an apolipoprotein determined at 2.5-Å resolution. Biochemistry. 30:1991;603-608.
17. Brouillette C.G., Jones J.L., Ng T.C., Kercret H., Chung B.H., Segrest J.P. Structural studies of apolipoprotein A-I/phosphatidylcholine recombinants by high-field proton NMR, nondenaturing gradient gel electrophoresis, and electron microscopy. Biochemistry. 23:1984;359-367.
18. Brouillette C.G., Anantharamaiah G.M., Engler J.A., Borhani D.W. Structural models of human apolipoprotein A-I. a critical analysis and review Biochim. Biophys. Acta. 1531:2001;4-46.
19. Bruckert E., von Eckardstein A., Funke H., Beucler I., Wiebusch H., Turpin G., Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis. 128:1997;121-128.
20. Buchko G.W., Rozek A., Kanda P., Kennedy M.A., Cushley R.J. Structural studies of a baboon (Papio sp) plasma protein inhibitor of cholesteryl ester transferase. Prot. Sci. 8:2000;1548-1558.
21. Carter D.B., Dunn E., McKinley D.D., Stratman N.C., Boyle T.P., Kuiper S.L., Oostveen J.A., Weaver R.J., Boller J.A., Gurney M.E. Human apolipoprotein E4 accelerates β-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50:2001;468-475.
22. Cedazo-Minguez A., Cowburn R.F. Apolipoprotein E. a major piece in the Alzheimer's disease puzzle J. Cell. Mol. Med. 5:2001;254-266.
23. Clement-Collin V., Leroy A., Monteilhet C., Aggerbeck L.P. Mimicking lipid-binding-induced conformational changes in the human apolipoprotein E N-terminal receptor binding domain effects of low pH and propanol. Eur. J. Biochem. 264:1999;358-368.
24. Conde-Knape K., Bensadoun A., Sobel J.H., Cohn J.S., Shachter N.S. Overexpression of apoC-I in apoE-null mice. severe hypertriglyceridemia due to inhibition of hepatic lipase J. Lipid Res. 43:2002;2136-2145.
25. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
26. Davison P.J., Norton P., Wallis S.C., Gill L., Cook M., Williamson R., Humphries S.R. There are two gene sequences for human apolipoprotein C1 (APO C1) on chromosome 19, one of which is 4. kb from the gene for apoE Biochem. Biophys. Res. Commun. 136:1986;876-884.
27. de Bakker P.I., Bateman A., Burke D.F., Miguel R.N., Mizuguchi K., Shi J., Shirai H., Blundell T.L. HOMSTRAD. adding sequence information to structure-based alignments of homologous protein families Bioinformatics. 17:2001;748-749.
28. De Pauw M., Vanloo B., Weisgraber K., Rosseneu M. Comparison of lipid-binding and lecithin. Cholesterol acyltransferase activation of the amino- and carboxyl-terminal domains of human apolipoprotein E3 Biochemistry. 34:1995;10953-10960.
29. Dumon M.F., Clerc M. Preliminary report on a case of apolipoprotein CI and CII deficiency. Clin. Chim. Acta. 157:1986;239-248.
30. Epand R.M. The apparent preferential interactions of human plasma high-density apolipoprotein A-1 with gel-state phospholipids. Biophys. Biochem. Acta. 712:1982;146-151.
31. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
32. Fielding C.J., Shore V.G., Fielding P.E. A protein cofactor of lecithin. cholesterol acyltransferase Biochem. Biophys. Res. Commun. 46:1972;1493-1498.
33. Franceschini G., Vecchio G., Gianfranceschi G., Magani D., Sirtori C.R. Apolipoprotein AI Milano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J. Biol. Chem. 260:1985;16321-16325.
34. Gautier T., Masson D., Pais de Barros J-P., Athias A., Gambert P., Aunis D., Metz-Boutigue M-H., Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 275:2000;37504-37509.
35. Gursky O., Atkinson D. Thermal unfolding of human high-density apolipoprotein A-1. implications for a lipid-free molten globular state Proc. Natl. Acad. Sci. USA. 93:1996;2991-2995.
36. Hatters D.M., Howlett G.J. The structural basis for amyloid formation by plasma apolipoproteins. a review Eur. Biophys. J. 31:2002;2-8.
37. Hatters D.M., Minton A.P., Howlett G.J. Macromolecular crowding accelerates amyloid formation by human apolipoprotein C-II. Biochemistry. 277:2002;7824-7830.
38. Hatters D.M., Wilson M.R., Easterbrook-Smith S.B., Howlett G.J. Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Eur. J. Biochem. 269:2002;2789-2794.
39. Ishigami M., Swerfeger D.K., Granholm N.A., Hui D.Y. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J. Biol. Chem. 273:1998;20156-20161.
40. Ito Y., Breslow J.L., Chait B.T. Apolipoprotein C-III-0 lacks carbohydrate residues. use of mass spectrometry to study apolipoprotein structure J. Lipid Res. 30:1989;1781-1787.
41. Jonas A. Regulation of lecithin cholesterol acyltransferase activity. Prog. Lipid Res. 37:1998;209-234.
42. Jong M.C., Havekes L.M. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. Int. J. Tissue React. 22:2000;59-66.
43. Jong M.C., Dahlmans V.E.H., van Gorp P.J.J., Willems van Dijk K., Koopmans S-J., Chan L., Hofker M.H., Havekes L.M. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98:1996;2259-2267.
44. Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism. Functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19:1999;472-484.
45. Jong M.C., Voshol P.J., Muurling M., Dahlmans V.E., Romijn J.A., Pijl H., Havekes L.M. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes. 50:2001;2779-2785.
46. Kamtekar S., Hecht M.H. Protein motifs 7. The four-helix bundle. what determines a fold? FASEB J. 9:1995;1013-1022.
47. Katzman R. Apolipoprotein E and Alzheimer's disease. Curr. Opin. Neurobiol. 4:1994;703-707.
48. Kawooya J.K., Meredith S.C., Wells M.A., Kezdy F.J., Law J.H. Physical and surface properties of insect apolipophorin III. J. Biol. Chem. 261:1986;13588-13591.
49. Kessler J.C., Rochet J.C., Lansbury P.T. Jr. The N-terminal repeat domain of α-synuclein inhibits β-sheet and amyloid fibril formation. Biochemistry. 42:2003;672-678.
50. Kindy M.S., Yu J., Guo J.T., Zhu H. Apolipoprotein serum amyloid A in Alzheimer's disease. J. Alzheimer Dis. 1:1999;155-167.
51. Kinnunen P.K.J., Ehnholm C. Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 65:1976;354-357.
52. Kinnunen P.K., Jackson R.L., Smith L.C., Gotto A.M., Sparrow J.T. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc. Natl. Acad. Sci. USA. 74:1977;4848-4851.
53. Kitagawa K., Matsumoto M., Hori M., Yanagihara T. Neuroprotective effect of apolipoprotein E against ischemia. Ann. N.Y. Acad. Sci. 977:2002;468-475.
54. Klon A.E., Segrest J.P., Harvey S.C. Molecular dynamics simulations on discoidal HDL particles suggest a mechanism for rotation in the apo A-I belt model. J. Mol. Biol. 324:2002;703-721.
55. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoprotein E and C on lipoprotein binding to the low density lipoprotein receptor-related protein. J. Biol. Chem. 265:1990;10771-10779.
56. Kumar M.S., Carson M., Hussain M.M., Murthy H.K.M. Structures of apolipoprotein A-II and a lipid-surrogate complex provide insights into apolipoprotein-lipid interactions. Biochemistry. 41:2002;11681-11691.
57. Laffont I., Takahashi M., Shibukawa Y., Honke K., Shuvaev V.V., Siest G., Visvikis S., Taniguchi N. Apolipoprotein E activates Akt pathway in neuro-2a in an isoform-specific manner. Biochem. Biophys. Res. Commun. 292:2002;83-87.
58. Lagocki P.A., Scanu A.M. In vitro modulation of the apolipoprotein composition of high density lipoprotein displacement of apolipoprotein A-I from high density lipoprotein by apolipoprotein A-II. J. Biol. Chem. 255:1980;3701-3706.
59. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK. a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26:1993;283-291.
60. Lauer S., Walker D., Elshourbagy N.A., Reardon C.A., Levy-Wilson B., Taylor J.M. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J. Biol. Chem. 263:1988;7277-7286.
61. Li H.H., Lyles D.S., Pan W., Alexander E., Thomas M.J., Sorci-Thomas M.G. ApoA-I structure on discs and spheres variable helix registry and conformational states. J. Biol. Chem. 277:2002;39093-39101.
62. Liu T., Krieger M., Kan H.Y., Zannis V.I. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J. Biol. Chem. 277:2002;21576-21584.
63. MacPhee C.E., Howlett G.J., Sawyer W.H. Mass spectrometry to characterize the binding of a peptide to a lipid surface. Anal. Biochem. 275:1999;22-29.
64. MacPhee C.E., Hatters D.M., Sawyer W.H., Howlett G.J. Apolipoprotein C-II 39-62 activates lipoprotein lipase by direct lipid-independent binding. Biochemistry. 39:2000;3433-3440.
65. MacRaild C.A., Hatters D.M., Howlett G.J., Gooley P.R. NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate. Biochemistry. 40:2001;5414-5421.
66. Major A.S., Dove D.E., Ishiguro H., Su Y.R., Brown A.M., Liu L., Carter K.J., Linton M.F., Fazio S. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice. Arterioscler. Thromb. Vasc. Biol. 21:2001;1790-1795.
67. Miguel R.N., Shi J., Mizuguchi K. Protein fold recognition and comparative modeling using HOMSTRAD, JOY and FUGUE. Tsigelny I. Protein Structure Prediction: Bioinformatic Approach. 2002;International University Line Publishers, La Jolla, CA.
68. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat. Genet. 14:1996;55-61.
69. Mizuguchi K., Deane C.M., Blundell T.L., Johnson M.S., Overington J.P. JOY. protein sequence-structure representation and analysis Bioinformatics. 14:1998;617-623.
70. Myklebost O., Williamson B., Markham A.F., Myklebost S.R., Rogers J., Woods D.E., Humphries S.E. The isolation and characterization of cDNA clones for human apolipoprotein CII. J. Biol. Chem. 259:1984;4401-4404.
71. Narayanaswami V., Wang J., Kay C.M., Scraba D.G., Ryan R.O. Disulfide bond engineering to monitor conformational opening of apolipophorin III during lipid binding. J. Biol. Chem. 271:1996;26855-26862.
72. Nettleton E.J., Sunde M., Lai Z., Kelly J.W., Dobson C.M., Robinson C.V. Protein subunit interactions and structural integrity of amyloidogenic transthyretins. evidence from electrospray mass spectrometry J. Mol. Biol. 281:1998;553-564.
73. Nichols A.V., Gong E.L., Blanche P.J., Forte T.M., Shore V.G. Interaction of model discoidal complexes of phosphatidylcholine and apolipoprotein A-I with plasma components physical and chemical properties of the transformed complexes. Biochim. Biophys. Acta. 793:1984;325-337.
74. Obici L., Bellotti V., Mangione P., Stoppini M., Arbistini E., Vega L., Zorzoli I., Anesi E., Zanotti G., Campana C., Vigano M., Merlini G. The new apolipoprotein A-I variant Leu(174)→Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am. J. Pathol. 155:1999;695-702.
75. Okon M., Frank P.G., Marcel Y.L., Cushley R.J. Secondary structure of human apolipoprotein A-I(1-186) in lipid-mimetic solution. FEBS Lett. 487:2001;390-396.
76. Okubo M., Hasegawa Y., Aoyama Y., Murase T. A G11 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency. a possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient Atherosclerosis. 130:1997;153-160.
77. Petit-Turcotte C., Stohl S.M., Beffert U., Cohn J.S., Aumont N., Tremblay M., Dea D., Yang L., Porier J., Shachter N.S. Apolipoprotein C-I expression in the brain in Alzheimer's disease. Neurobiol. Dis. 8:2001;953-963.
78. Pham C.L., Hatters D.M., Lawrence L.J., Howlett G.J. Cross-linking and amyloid formation by N- and C-terminal cysteine derivatives of human apolipoprotein C-II. Biochemistry. 41:2002;14313-14322.
79. Poeggeler B., Miravalle L., Zagorski M.G., Wisniewski T., Chyan Y.J., Zhang Y., Shao H., Bryant-Thomas T., Vidal R., Frangione B., Ghiso J., Pappolla M.A. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide. Biochemistry. 40:2001;14995-15001.
80. Privalov P.L. Thermodynamic problems of protein structure. Annu. Rev. Biophys. Biophys. Chem. 18:1989;47-69.
81. Raussens V., Narayanaswami V., Goormaghtigh E., Ryan R.O., Ruysschaert J-M. Hydrogen/deuterium exchange kinetics of apolipophorin-III in lipid-free and phospholipid-bound states an analysis by Fourier transform infrared spectroscopy. J. Biol. Chem. 271:1996;23089-23093.
82. Reschly E.J., Sorci-Thomas M.G., Davidson W.S., Meredith S.C., Reardon C.A., Getz G.S. Apolipoprotein A-I α-helices 7 and 8 modulate high density lipoprotein subclass distribution. J. Biol. Chem. 277:2002;9645-9654.
83. Riddell D.R., Graham A., Owen J.S. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. implications for vascular disease J. Biol. Chem. 272:1997;89-95.
84. Rozek A., Buchko G.W., Cushley R.J. Conformation of two peptides corresponding to human apolipoprotein C-I residues 7-23 and 35-53 in the presence of sodium dodecyl sulfate by CD and NMR spectroscopy. Biochemistry. 324:1995;7401-7408.
85. 1H NMR spectroscopy. Protein Sci. 6:1997;1858-1868.
86. Rozwarski D.A., Gronenborn A.M., Clore G.M., Bazan J.F., Bohm A., Wlodawer A., Hatada M., Karplus P.A. Structural comparisons among the short-chain helical cytokines. Structure. 2:1994;159-173.
87. Ryan R.O., Oikawa K., Kay C.M. Conformational, thermodynamic, and stability properties of Manduca sexta apolipophorin III. J. Biol. Chem. 268:1993;1525-1530.
88. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:1993;779-815.
89. Schachter F., Faure-Delanef L., Guenot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6:1994;29-32.
90. Schaefer E.J., Ordovas J., Law S., Ghiselli G., Kashyap L., Srivastava L., Heaton W.H., Albers J., Connor W., Lindgren F. Familial apolipoprotein A-I and C-III deficiency. variant II J. Lipid Res. 26:1985;1089-1101.
91. Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M., Laggner P., Prassl R. Crystal structure of human β2-glycoprotein I. implications for phospholipid binding and the antiphospholipid syndrome EMBO J. 18:1999;6228-6239.
92. Segrest J.P., Jones M.K., Klon A.E., Sheldahl C.J., Hellinger M., De Loof H., Harvey S.C. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 274:1999;31755-31758.
93. Shah P.K., Yano J., Reyes O., Chyu K.Y., Kaul S., Bisgaier C.L., Drake S., Cercek B. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice potential implications for acute plaque stabilization. Circulation. 103:2001;3047-3050.
94. Shi J., Blundell T.L., Mizuguchi K. FUGUE. sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties J. Mol. Biol. 310:2001;243-257.
95. Shulmann R.S., Herbert P.N., Wehrly K., Frederickson D.S. The complete amino acid sequence of C-I (apoLP-Ser), an apolipoprotein from human very low density lipoproteins. J. Biol. Chem. 250:1975;182-190.
96. Soulages J.L., Arrese E.L. Interaction of the α-helices of apolipophorin III with the phospholipid acyl chains in discoidal lipoprotein particles. a fluorescence quenching study Biochemistry. 40:2001;14279-14290.
97. Soulages J.L., Bendavid O.J. The lipid binding activity of the exchangeable apolipoprotein apolipophorin-III correlates with the formation of a partially folded conformation. Biochemistry. 37:1998;10203-10210.
98. Soulages J.L., Salamon Z., Wells M.A., Tollin G. Low concentrations of diacylglycerol promote the binding of apolipophorin III to a phospholipid bilayer. a surface plasmon resonance spectroscopy study Proc. Natl. Acad. Sci. USA. 92:1995;5650-5654.
99. Soutar A.K., Garner C.W., Baker H.N., Sparrow J.T., Jackson R.L., Gotto A.M. Jr., Smith L.C. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin. cholesterol acyl-transferase Biochemistry. 14:1975;3057-3064.
100. Sparks D.L., Pritchard P.H. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein. effect of HDL lipid and apolipoprotein content J. Lipid Res. 30:1989;1491-1498.
101. Sparrow J.T., Pownall H.J., Hsu F-J., Blumenthal L.D., Culwell A.R., Gotto A.M. Lipid binding by fragments of apolipoprotein CIII-1 obtained by thrombin cleavage. Biochemistry. 16:1977;5427-5431.
102. Sprecher D.L., Taam L., Brewer H.B. Jr. Two-dimensional electrophoresis of human plasma apolipoproteins. Clin. Chem. 30:1984;2084-2092.
103. Subbaiah P.V., Norum R.A., Bagdade J.D. Effect of apolipoprotein activators on the specificity of lecithin:cholesterol acyltransferase. determination of cholesteryl esters formed in A-I/C-III deficiency J. Lipid Res. 32:1991;1601-1609.
104. Tricerri M.A., Behling Agree A.K., Sanchez S.A., Bronski J., Jonas A. Arrangement of apolipoprotein A-I in reconstituted high-density lipoprotein disks. an alternative model based on fluorescence resonance energy transfer experiments Biochemistry. 40:2001;5065-5074.
105. Trieu V.N., McConathy W.J. APOC-III-β-galactosidase hybrid distinguishes between VLDL and LDL phospholipids. Biochem. Biophys. Res. Commun. 211:1995;754-760.
106. Vadiveloo P.K., Allan C.M., Murray B.J., Fidge N.H. Interaction of apolipoprotein AII with the putative high-density lipoprotein receptor. Biochemistry. 32:1993;9480-9485.
107. Vlassi M., Cesareni G., Kokkinidis M. A correlation between the loss of hydrophobic core packing interactions and protein stability. J. Mol. Biol. 285:1999;817-827.
108. Wang G. How the lipid-free structure of the N-terminal truncated human apoA-I converts to the lipid-bound form. new insights from NMR and X-ray structural comparison FEBS Lett. 529:2002;157-161.
109. Wang J., Sykes B.D., Ryan R.O. Structural basis for the conformational adaptability of apolipophorin III, a helix-bundle exchangeable apolipoprotein. Proc. Natl. Acad. Sci. USA. 99:2002;1188-1193.
110. Weers P.M.M., Kay C.M., Oikawa K., Wientzek M., Van der Horst D.J., Ryan R.O. Factors affecting the stability and conformation of Locusta migratoria apolipophorin III. Biochemistry. 33:1994;3617-3624.
111. Weisgraber K.H., Bersot T.P., Mahley R.W., Franceschini G., Sirtori C.R. A-I milano apoprotein isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J. Clin. Invest. 66:1980;901-907.
112. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 252:1991;1817-1822.
113. Xiong W., Li W-H., Posner I., Yamamura T., Yamamoto A., Gotto A.M. Jr., Chan L. No severe bottleneck during human evolution. evidence from two apolipoprotein C-II deficiency alleles Am. J. Hum. Genet. 48:1991;383-389.
114. Yazaki M., Liepnieks J.J., Yamashita T., Guenther B., Skinner M., Benson M.D. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int. 60:2001;1658-1665.
115. Zhou X.H., Paulsson G., Stemme S., Hansson G.K. Hypercholesterolemia is associated with a T helper (Th) 1 Th2 switch of autoimmune response in atherosclerotic apoE knockout mice. J. Clin. Invest. 101:1998;1717-1725.